8-K filing — LeonaBio, Inc. (LONA)
Filed: 2026-09-22 AccNo: 0001193125-26-397952 Size: 154 KB Item 8.01: Other Events
Stocks · News reference
LeonaBio Q2 EPS $(0.80) Beats $(1.36) Estimate
LeonaBio (NASDAQ:LONA) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $(1.36) by 41.18 percent. This is a 55.56 percent increase over losses of $(1.80) per share from the
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
LeonaBio Enrolls 500th Subject In Phase 3 ELAINE-3 Trial For Lasofoxifene With Abemaciclib
On August 26, 2026, LeonaBio, Inc. (the "Company") announced that it had enrolled the 500th subject in its ongoing Phase 3 ELAINE-3 clinical trial (NCT05696626) for lasofoxifene in combination with abemaciclib,
Mizuho Maintains Outperform on LeonaBio, Lowers Price Target to $15
Mizuho analyst Graig Suvannavejh maintains LeonaBio (NASDAQ:LONA) with a Outperform and lowers the price target from $16 to $15.
Citizens Maintains Market Outperform on LeonaBio, Lowers Price Target to $17
Citizens analyst Jason N. Butler maintains LeonaBio (NASDAQ:LONA) with a Market Outperform and lowers the price target from $18 to $17.